UNSPSC 51393412: Tazifylline hydrochloride

This classification denotes a bronchodilator with the molecular formula C23H32N6O3S.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 409R6U6UEI, chemically known as 1h-purine-2,6-dione, 3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl-, dihydrochloride, (+-)- but more generally known as tazifylline hydrochloride, which bears US NIH Compound Identifier 54423. Most nations, for tariff and trade purposes, schedule tazifylline hydrochloride under HS 29395900 and SITC 54145.

As of Q4 2014, TAZIFYLLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Tazifylline hydrochloride bears US NLM identifiers UMLS ID C0126094 and NCI Concept Code C96197. SMILES: CN1C2C(C(=O)N(C1=O)C)N(CN2)CC(CN3CCN(CC3)CCCSC4CCCCC4)O.CL.CL.

UNSPSC 51393412 Tazifylline hydrochloride is a Commodity code for a specific pharmaceutical product, but the recent state and local procurement activity tagged under this code does not reflect purchases of tazifylline. Instead, Seminole County, Florida posted an IFB (Invitation for Bid) in June 2026 for naloxone and drug deactivation systems — medications and equipment unrelated to the code's nominal scope. This mismatch suggests the code shows little relevant recent activity aligned with tazifylline procurement at the state and local level. The single available record indicates that when pharmaceutical procurement does appear in this tier, it may involve emergency-response medications and harm-reduction supplies procured by county health departments through competitive bidding, with multi-year terms and renewal options.

The geographic reach captured by the source extends only to Florida, specifically Seminole County. The Seminole County naloxone and drug deactivation systems procurement, posted June 30, 2026, with a response deadline of July 26, 2023 (a date discrepancy in the source record), required quarterly deliveries to the county community health building and included standard state and local compliance requirements such as E-Verify and drug-free workplace certification. The contract structure included a two-year initial term with a one-year renewal option and a three-month probationary termination clause. No other state or local opportunities under this UNSPSC code appear in the recent record, limiting visibility into issuing-body mix or geographic concentration.